Eascra Biotech Named to Fast Company’s “Next Big Things in Tech 2025”
Recognition for groundbreaking work and pioneering space manufacturing
BOSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Fast Company has named Eascra Biotech, a nanomedicine startup, to its annual Next Big Things in Tech list for 2025. Fast Company is recognizing Eascra’s groundbreaking work using microgravity to manufacture therapeutic nanomaterials aboard the International Space Station (ISS).
Eascra is one of five companies honored in the Space and Telecom category for “making the International Space Station a pharmaceutical research lab,” and one of 137 total honorees. The list celebrates projects that “represent genuinely new ideas in significant fields, have already demonstrated progress, and hold the potential for further growth.” These projects span 31 different technology sectors, including applied AI, sustainability, robotics, quantum computing, and space innovation.
“Being included in Fast Company’s Next Big Things in Tech list is wonderful visibility and validation for our vision of space-enabled manufacturing,” said Mari Anne Snow, Eascra co-founder and CEO. “The ability to fabricate nanomaterials in low Earth orbit opens new possibilities for safer, more stable therapeutics, advancing healthcare here on Earth.”
The Eascra team just completed their fifth mission on the International Space Station in less than two years and is the first commercial company to produce nanoparticles in space for medical use on Earth. Eascra recently received an NSF Small Business Innovation Research (SBIR) grant, an AFWERX SBIR grant and has obtained more than $8M in grants, awards and commercial-sponsored research deals from organizations including NASA and MassVentures.
Eascra’s JBNp technology, pioneered by Eascra cofounder Dr. Yupeng Chen, a professor of biomedical engineering at the University of Connecticut, delivers RNA therapeutics to hard-to-penetrate tissues like cartilage and solid tumors. Eascra’s proprietary nanoparticles are highly versatile and able to maintain fragile cargos like mRNA at room temperature for extended periods, thus eliminating cold chain requirements.
About Eascra Biotech
Eascra Biotech (eascrabiotech.com) is an early-stage nanomedicine startup providing an advanced therapeutic delivery platform capable of delivering nucleotides, gene editing, and other therapeutics to hard-to-reach treatment sites, such as articular cartilage, kidneys and solid tumors. Our mission is to advance our technology for the benefit of humankind. Eascra’s proprietary delivery mechanism, a Janus Base Nanoparticle (JBNp) invented by Eascra co-founder, Dr. Yupeng Chen, mimics DNA and is customizable for different treatment indications. Eascra is working with NASA, the ISS National Laboratory™, and a variety of private space companies to accelerate our go-to-market strategy. We are actively seeking commercial partnerships with companies in need of innovative delivery mechanisms to expedite the development of cutting-edge treatments that enhance patient outcomes on Earth.
Media Contact: Bobbie Carlton Carlton PR & Marketing LLC Bobbie@carltonprmarketing.com 781-718-7619
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
